The effect of spironolactone upon corticosteroid hormone metabolism in patients with early stage chronic kidney disease

Clinical Endocrinology

Volumn 73, Issue 5, 2010, Pages 566-572

  Hammer, Fabian ^a   Edwards, Nicola C ^b   Hughes, Beverly A ^a   Steeds, Richard P ^b   Ferro, Charles J ^b   Townend, Jonathan N ^b   Stewart, Paul M ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANGIOTENSIN II; CORTICOSTEROID; PLACEBO; SPIRONOLACTONE; STEROID 11BETA MONOOXYGENASE; TETRAHYDROCORTISOL; TETRAHYDROCORTISONE; TETRAHYDRODEOXYCORTICOSTERONE;

ADULT; AGED; ALDOSTERONE BLOOD LEVEL; ARTICLE; BODY MASS; BODY WEIGHT; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID METABOLISM; CORTICOSTEROID RELEASE; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ENZYME ACTIVITY; FEMALE; GAS CHROMATOGRAPHY; GLOMERULUS FILTRATION RATE; HUMAN; HYDROCORTISONE URINE LEVEL; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE;

ADRENAL CORTEX HORMONES; ADULT; AGED; ALDOSTERONE; ANGIOTENSIN II; BLOOD PRESSURE; FEMALE; HUMANS; HYDROCORTISONE; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RECEPTORS, MINERALOCORTICOID; RENAL INSUFFICIENCY, CHRONIC; RENIN; SPIRONOLACTONE; TETRAHYDROCORTISOL;

EID: 78449273890     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2010.03832.x     Document Type: Article

References (41)

1. Hillege, H.L., Girbes, A.R., De Kam, P.J., et al. (2000) Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation, 102, 203 - 210.
2. Go, A.S., Chertow, G.M., Fan, D., et al. (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. The New England Journal of Medicine, 351, 1296 - 1305.
3. Mann, J.F., Gerstein, H.C., Pogue, J., et al. (2002) Cardiovascular risk in patients with early renal insufficiency: implications for the use of ACE inhibitors. American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions, 2, 157 - 162.
4. Tonelli, M., Wiebe, N., Culleton, B., et al. (2006) Chronic kidney disease and mortality risk: a systematic review. Journal of the American Society of Nephrology: JASN, 17, 2034 - 2047.
5. Tylicki, L., Rutkowski, P., Renke, M., et al. (2008) Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial. American Journal of Kidney Diseases: The Official Journal of the National Kidney Foundation, 52, 486 - 493.
6. Pitt, B., Remme, W., Zannad, F., et al. (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. The New England Journal of Medicine, 348, 1309 - 1321.
7. Pitt, B., Zannad, F., Remme, W.J., et al. (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. The New England Journal of Medicine, 341, 709 - 717.
8. Arriza, J.L., Weinberger, C., Cerelli, G., et al. (1987) Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science, 237, 268 - 275.
9. Agarwal, A.K., Giacchetti, G., Lavery, G., et al. (2000) CA-Repeat polymorphism in intron 1 of HSD11B2: effects on gene expression and salt sensitivity. Hypertension, 36, 187 - 194.
10. Lovati, E., Ferrari, P., Dick, B., et al. (1999) Molecular basis of human salt sensitivity: the role of the 11beta-hydroxysteroid dehydrogenase type 2. The Journal of Clinical Endocrinology and Metabolism, 84, 3745 - 3749.
11. N'Gankam, V., Uehlinger, D., Dick, B., et al. (2002) Increased cortisol metabolites and reduced activity of 11beta-hydroxysteroid dehydrogenase in patients on hemodialysis. Kidney International, 61, 1859 - 1866.
12. Whitworth, J.A., Stewart, P.M., Burt, D., et al. (1989) The kidney is the major site of cortisone production in man. Clinical Endocrinology, 31, 355 - 361.
13. Quinkler, M., Zehnder, D., Lepenies, J., et al. (2005) Expression of renal 11beta-hydroxysteroid dehydrogenase type 2 is decreased in patients with impaired renal function. European Journal of Endocrinology/European Federation of Endocrine Societies, 153, 291 - 299.
14. Cheng, S.C., Suzuki, K., Sadee, W., et al. (1976) Effects of spironolactone, canrenone and canrenoate-K on cytochrome P450, and 11beta- and 18-hydroxylation in bovine and human adrenal cortical mitochondria. Endocrinology, 99, 1097 - 1106.
15. Greiner, J.W., Kramer, R.E., Jarrell, J., et al. (1976) Mechanism of action of spironolactone on adrenocortical function in guinea pigs. The Journal of Pharmacology and Experimental Therapeutics, 198, 709 - 715.
16. Heuser, I., Deuschle, M., Weber, B., et al. (2000) Increased activity of the hypothalamus-pituitary-adrenal system after treatment with the mineralocorticoid receptor antagonist spironolactone. Psychoneuroendocrinology, 25, 513 - 518.
17. Young, E.A., Lopez, J.F., Murphy-Weinberg, V., et al. (1998) The role of mineralocorticoid receptors in hypothalamic-pituitary-adrenal axis regulation in humans. The Journal of Clinical Endocrinology and Metabolism, 83, 3339 - 3345.
18. Edwards, N.C., Steeds, R.P., Stewart, P.M., et al. (2009) Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial. Journal of the American College of Cardiology, 54, 505 - 512.
19. Sarnak, M.J., Levey, A.S., Schoolwerth, A.C., et al. (2003) Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation, 108, 2154 - 2169.
20. Millar, J.A., Leckie, B.J., Morton, J.J., et al. (1980) A microassay for active and total renin concentration in human plasma based on antibody trapping. Clinica Chimica Acta; International Journal of Clinical Chemistry, 101, 5 - 15.
21. Morton, J.J., &, Webb, D.J., (1985) Measurement of plasma angiotensin II. Clinical Science (London, England: 1979), 68, 483 - 484.
22. Palermo, M., Shackleton, C.H., Mantero, F., et al. (1996) Urinary free cortisone and the assessment of 11 beta-hydroxysteroid dehydrogenase activity in man. Clinical Endocrinology, 45, 605 - 611.
23. Walker, E.A., Ahmed, A., Lavery, G.G., et al. (2007) 11beta- hydroxysteroid dehydrogenase type 1 regulation by intracellular glucose 6-phosphate provides evidence for a novel link between glucose metabolism and hypothalamo-pituitary-adrenal axis function. Journal of Biological Chemistry, 282, 27030 - 27036.
24. Freel, E.M., Ingram, M., Friel, E.C., et al. (2007) Phenotypic consequences of variation across the aldosterone synthase and 11-beta hydroxylase locus in a hypertensive cohort: data from the MRC BRIGHT Study. Clin Endocrinol (Oxf), 67, 832 - 838.
25. Kidambi, S., Kotchen, J.M., Grim, C.E., et al. (2007) Association of adrenal steroids with hypertension and the metabolic syndrome in blacks. Hypertension, 49, 704 - 711.
26. Cascella, T., Palomba, S., Tauchmanova, L., et al. (2006) Serum aldosterone concentration and cardiovascular risk in women with polycystic ovarian syndrome. The Journal of Clinical Endocrinology and Metabolism, 91, 4395 - 4400.
27. Haddad, N., Rajan, J., Nagaraja, H.N., et al. (2007) Usual ACE inhibitor therapy in CKD patients is associated with lower plasma aldosterone levels than usual angiotensin receptor blocker therapy. Kidney & Blood Pressure Research, 30, 299 - 305.
28. Andrew, R., Gale, C.R., Walker, B.R., et al. (2002) Glucocorticoid metabolism and the metabolic syndrome: associations in an elderly cohort. Experimental and Clinical Endocrinology & Diabetes: Official Journal, German Society of Endocrinology [and] German Diabetes Association, 110, 284 - 290.
29. Hammer, F., &, Stewart, P.M., (2006) Cortisol metabolism in hypertension. Best Practice & Research. Clinical endocrinology & Metabolism, 20, 337 - 353.
30. Guder, G., Bauersachs, J., Frantz, S., et al. (2007) Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure. Circulation, 115, 1754 - 1761.
31. Rousseau, M.F., Gurne, O., Duprez, D., et al. (2002) Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: results from the RALES neurohormonal substudy. Journal of the American College of Cardiology, 40, 1596 - 1601.
32. Bird, I.M., Hanley, N.A., Word, R.A., et al. (1993) Human NCI-H295 adrenocortical carcinoma cells: a model for angiotensin-II-responsive aldosterone secretion. Endocrinology, 133, 1555 - 1561.
33. Pryce, C.R., (2008) Postnatal ontogeny of expression of the corticosteroid receptor genes in mammalian brains: inter-species and intra-species differences. Brain Research Reviews, 57, 596 - 605.
34. De Kloet, E.R., Vreugdenhil, E., Oitzl, M.S., et al. (1998) Brain corticosteroid receptor balance in health and disease. Endocrine Reviews, 19, 269 - 301.
35. Jacobson, L., &, Sapolsky, R., (1991) The role of the hippocampus in feedback regulation of the hypothalamic-pituitary-adrenocortical axis. Endocrine Reviews, 12, 118 - 134.
36. Rupprecht, R., Arriza, J.L., Spengler, D., et al. (1993) Transactivation and synergistic properties of the mineralocorticoid receptor: relationship to the glucocorticoid receptor. Molecular Endocrinology (Baltimore, Md.), 7, 597 - 603.
37. Arvat, E., Maccagno, B., Giordano, R., et al. (2001) Mineralocorticoid receptor blockade by canrenoate increases both spontaneous and stimulated adrenal function in humans. The Journal of Clinical Endocrinology and Metabolism, 86, 3176 - 3181.
38. Dodt, C., Kern, W., Fehm, H.L., et al. (1993) Antimineralocorticoid canrenoate enhances secretory activity of the hypothalamus-pituitary- adrenocortical (HPA) axis in humans. Neuroendocrinology, 58, 570 - 574.
39. Grottoli, S., Giordano, R., Maccagno, B., et al. (2002) The stimulatory effect of canrenoate, a mineralocorticoid antagonist, on the activity of the hypothalamus-pituitary-adrenal axis is abolished by alprazolam, a benzodiazepine, in humans. The Journal of Clinical Endocrinology and Metabolism, 87, 4616 - 4620.
40. Mattsson, C., Reynolds, R.M., Simonyte, K., et al. (2009) Combined receptor antagonist stimulation of the HPA axis test identifies impaired negative feedback sensitivity to cortisol in obese men. The Journal of Clinical Endocrinology and Metabolism, 4, 1347 - 1352.
41. Stewart, P.M., Corrie, J.E., Shackleton, C.H., et al. (1988) Syndrome of apparent mineralocorticoid excess. A defect in the cortisol-cortisone shuttle. The Journal of Clinical Investigation, 82, 340 - 349.